sub-1

PfSUB1-IN-1 (compound 4c) 作为一种针对恶性疟原虫的PfSUB1(丝氨酸蛋白酶样酶1)有效的抑制剂 (IC50: 15 nM),具有显著的抗疟作用.该化合物对表达PfSUB1水平较低的转基因恶性疟原虫株具备较野生型寄生虫株高13倍的抑制效能.

Polyoxin C is a nucleoside antibiotic.

ARN25068是三种蛋白激酶(GSK-3β、FYN和DYRK1A)的亚微摩尔抑制剂，可用于治疗tau相关神经系统疾病。

Dopamine D2 receptor antagonist-1，一种对多巴胺D2受体（D2R）表现出亚毫摩尔级别亲和力的负变构调节剂（NAM）。

Clindamycin hydrochloride monohydrate（Clindamycin alcoholate）是一种口服蛋白质合成抑制剂，具有在金黄色葡萄球菌中以亚抑制浓度(sub-MICs)抑制毒力因子表达的能力。其抗性来源于50S核糖体亚基（23S rRNA）的抗生素结合位点通过酶促甲基化。此外，Clindamycin hydrochloride monohydrate能显著减少杀白细胞毒素（PVL）、毒性休克-葡萄球菌毒素（TSST-1）或α-溶血素（Hla）的产生。

Ara-G 是一种脱氧鸟苷 (GdR) 类似物和核苷类似物，可被 T 淋巴谱系细胞迅速转化为其相应的阿拉伯糖基鸟嘌呤核苷酸三磷酸 (araGTP)，从而抑制 DNA 合成和对 T 淋巴母细胞的选择性体外毒性细胞系以及来自 T 细胞急性淋巴细胞白血病 (ALL) 患者的新鲜分离的白血病细胞。

Nur77 modulator 1 可与Nur77结合，KD 为 3.58 μM。它上调 Nur77 表达，介导Nur77亚细胞定位，诱导Nur77 依赖的内质网应激和自噬，可导致细胞凋亡，Nur77 modulator 1显示出抗肝癌生物活性。

GQN-B37-E 是一种针对MCL-1的高效选择性结合剂及抑制剂。该化合物特异性与MCL-1的BH3结合域相结合。在亚微摩尔水平 (Ki= 0.6 μM) 上，GQN-B37-E 显示出对MCL-1的高亲和力，而与BCL-2或BCL-XL的亲和力则相对较弱。

Neochilenin (3-O-Methylquercetin 4'-O-glucoside) 是一种从蜡菊亚科 (Cactaceae) 分离出的3-O-methylquercetin糖苷。

MeOIstPyrd是抗皮肤癌活性分子，其作用机制包括激活线粒体内在的细胞凋亡通路，从而抑制细胞的增殖、迁移及球体形成，并能诱导DNA损伤。此外，MeOIstPyrd还能激活p53蛋白、延长其半衰期，并通过ser15位点的磷酸化增强p53的稳定性。它通过与MDM2在p53子口袋内的结合位点互作，阻断p53与MDM2的相互作用。

CTL-12是一种Fatty Acid Synthase (FASN)抑制剂（IC50: 2.5 μM），能够诱导apoptosis。它使细胞周期在Sub-G1 S期停滞并增加caspase-9和凋亡标志物Bax的表达，同时减少抗凋亡标志物Bcl-xL的水平。CTL-12通过抑制de novo脂肪酸合成，切断了肿瘤细胞的代谢需求，是乳腺癌和结直肠癌研究中的重要工具。

JNK-1-IN-5 (Compound 14) 是一种高效的JNK1抑制剂，表现出亚纳摩尔效应，并能抑制TGF-β诱导的上皮-间质转化。该化合物在作为JNK1抗肺纤维化剂的研究中具有潜力。

MHY219 is a novel HDAC inhibitor. MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. MHY219 was shown to enhance the cytotoxicity on DU145 cells (IC50, 0.36 μM) when compared with LNCaP (IC50, 0.97 μM) and PC3 cells (IC50, 5.12 μM). MHY219 showed a potent inhibition of total HDAC activity when compared with SAHA. MHY219 increased histone H3 hyperacetylation and reduced the expression of class I HDACs (1, 2 and 3) in prostate cancer cells. MHY219 effectively increased the sub-G1 fraction of cells through p21 and p27 dependent pathways in DU145 cells. MHY219 significantly induced a G2 M phase arrest in DU145 and PC3 cells and arrested the cell cycle at G0 G1 phase in LNCaP cells. Furthermore, MHY219 effectively increased apoptosis in DU145 and LNCaP cells, but not PC3 cells, according to Annexin V PI staining and Western blot analysis. These results indicate that MHY219 is a potent HDAC inhibitor that targets regulating mu......

TTT-28 is a thiazole-valine peptidomimetic, and is a selective ABCB1 (P-gp MDR1) inhibitor with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated Multidrug resistance (MDR) by selectively blocki

GSK-345931A, an EP(1) receptor antagonist, shows measurable CNS penetration in the mouse and rat and potent analgesic efficacy in acute and sub-chronic models of inflammatory pain.

YW3-56 is a potent peptidylarginine deiminase (PAD) inhibitor, with an IC50 of 1-5 μM for PAD4. Compared with Cl-amidine, YW3-56 shows >60-fold increase in cell growth inhibition efficacy (IC50 about 2.5 μM) but only 5-fold increase in PAD4 inhibition (IC sub>50 about 1-5 μM). At 2-4 μM concentrations, YW3-56 displays mainly cytostatic effects by slowing cell division, whereas at higher concentrations, it exerts cytotoxic effects by altering cell morphology and killing cells[1]. [1]. Wang Y, et al. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and t he mammalian target of rapamycin complex 1 activity. J Biol Chem. 2012 Jul 27;287(31):25941-53.

VMY-1-103 is a potent CDK inhibitor, is also a novel dansylated analog of purvalanol B, was shown to inhibit cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B. VMY-1-103 , but not purvalanol B, significantly decreased the proportion of cells in S phase and increased the proportion of cells in G(2) M. VMY-1-103 increased the sub G(1) fraction of apoptotic cells, induced PARP and caspase-3 cleavage and increased the levels of the Death Receptors DR4 and DR5, Bax and Bad while decreasing the number of viable cells, all supporting apoptosis as a mechanism of cell death. VMY-1-103 possesses unique antiproliferative capabilities and that this compound may form the basis of a new candidate drug to treat medulloblastoma.

Nepetalactone is found in the plant Nepeta parnassica and has high mosquito repellency properties.

AZD5991是一种针对血液癌症治疗的高效选择性Mcl-1抑制剂。作为经过合理设计的大环形化合物，AZD5991对Mcl-1有亚纳摩尔级的亲和力。该化合物主要抑制诱导性髓系白血病细胞分化蛋白（myeloid cell leukemia-1; Mcl-1; Bcl2-L-3），具有潜在的促凋亡和抗肿瘤活性。使用时，AZD5991与Mcl-1结合，从而阻止Mcl-1与某些促凋亡蛋白的结合及其失活，进而促进过表达Mcl-1的细胞发生凋亡。

IM-93 抑制铁死亡(ferroptosis)和 坏死(NETosis)，抑制细胞死亡的IC50值为 0.45 μM。

DNA topoisomerase II inhibitor 1 是 DNA 拓扑异构酶 II 的有效抑制剂，能够将细胞周期停滞在亚 G1 期，并诱导细胞凋亡 (apoptosis) ，具有抗增值作用。

BACE1-IN-10为高效的BACE1抑制剂，对重组BACE1（rBACE1）显示出亚微摩尔级别的抑制活性。

Aculene D, 一种真菌代谢物，针对Chromobacterium violaceum CV026表现出群体感应(QS)抑制活性。该化合物能在亚抑制浓度下，显著削减由N-己酰基-l-高丝氨酸内酯(C6-HSL)触发的C. violaceum CV026培养物中紫罗兰素的产生。

HTR2A antagonist 1 (Compound 15f) 是一种 HTR2A 拮抗剂，IC50 为 42.79 nM。此化合物通过激活 p53 p21 caspase 3 信号通路引起结直肠癌细胞的亚 G1 期细胞周期阻滞和凋亡，并且展示良好的肝微粒体稳定性。HTR2A antagonist 1 可用于结直肠癌研究。